Defining Clinical Endpoints in LGMD

Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Nicholas Johnson, Associate Professor & Vice Chair of Research, Virginia Commonwealth University. The project is titled “Defining Clinical Endpoints in LGMD.”

What are COAs, and why do they matter to those living with LGMD?

Clinical outcome assessments (COAs) are measurements used during clinical trials to determine if an investigational drug or therapy provides benefit. As therapeutics are being developed for limb girdle muscular dystrophies (LGMDs), it is important to prepare for clinical trials by developing robust COAs that are sensitive to changes and represent aspects of the disease that are important to patients.

Dr. Johnson and colleagues recently established a Limb Girdle Muscular Dystrophy Clinical Research Network, funded by a grant from the Muscular Dystrophy Association, which brings together eight medical centers with significant expertise in LGMD research and clinical care. The current observational study will follow LGMD2A patients over a period of 12 months to establish which COAs are sensitive to normal disease progression, so that these may be used as tools during future clinical trials.

“A lack of standard COAs for LGMD2A is a barrier to therapy development for this disease. Dr. Johnson’s project will develop tools which will be used to determine if investigational drugs are effective in a clinical trial setting.”
— Jennifer Levy, Scientific Director, Coalition to Cure Calpain 3

“The development of gene replacement therapies has accelerated the need to prepare for clinical trials. We are excited to begin working with C3, the MDA, and the LGMD2A community to develop the tools necessary to test these potential treatments.”
— Dr. Nicholas Johnson

Recent Posts

  • Ruby Goldstein de Salazar Awarded C3 Travel Grant

    C3 awarded a Travel Grant to Ruby Goldstein de Salazar, a graduate student in Dr. Melissa Spencer’s laboratory at the University of California Los Angeles. Ms. Goldstein de Salazar traveled to Hiroshima, Japan in September 2026 to present her research at the 31st annual Congress of the World Muscle Society. Ms. Goldstein de Salazar’s presentation,... Read More
  • Djunda Ratenan-Peltier Awarded C3 Travel Grant

    C3 is pleased to announce that Djunda Ratenan-Peltier was awarded a Travel Grant for the presentation of her research at the international conference New Directions in Biology and Disease of Skeletal Muscle, which took place from June 7 to 10, 2026 in Fort Lauderdale, Florida. Ms. Ratenan-Peltier is a PhD student in Life Sciences at... Read More